Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)
Multiple myeloma is a type of blood cancer affecting plasma cells in the bone marrow. Many people have a stem cell transplant as part of their initial treatment. Even when tests show a great improvement, microscopic traces of cancer cells can sometimes remain. This is known as being 'MRD-positive'. The TiTan study is testing whether combining two newer targeted drugs (teclistamab and talquetamab) works better than the current standard maintenance treatment (daratumumab and lenalidomide). Both teclistamab and talquetamab help your own immune system find and attack cancer cells. Researchers want to see if this new combination can completely clear these remaining traces, prevent the cancer from returning for longer, and maintain a good quality of life. Half of the participants will receive the new combination, and the other half will receive standard care.
At a glance
What is this study about?
Multiple myeloma is a cancer that starts in the bone marrow, where blood cells are made. Modern treatments, such as an autologous stem cell transplant using a patient's own healthy cells, often push the cancer into deep remission. However, highly sensitive laboratory tests can sometimes detect tiny numbers of cancer cells that survived the treatment. Doctors call this minimal residual disease, or MRD. Finding and treating these leftover cells early may prevent the myeloma from returning.
The TiTan clinical trial looks at whether a new approach can wipe out these remaining cancer cells more effectively than current standard treatments. It compares two newer medicines, teclistamab and talquetamab, given together, against two well-established treatments, daratumumab and lenalidomide. Teclistamab and talquetamab are specialised types of treatments called bispecific antibodies. They act like a bridge, connecting your body's immune cells directly to myeloma cells to destroy them.
This study is important because completely clearing residual cancer cells may help people live longer, healthier lives without their disease returning. Researchers will closely track how many patients have no detectable cancer cells left after 12 months, how long patients stay free from disease, and how the treatments affect daily quality of life.
Key takeaways
- Tests a new two-drug combination against the current standard treatment for multiple myeloma.
- Aimed at adults who recently had a stem cell transplant but still have tiny traces of cancer left.
- A phase 3 study designed to see if the new approach keeps cancer away for longer.
- Participants are randomly assigned to either the new drugs or standard care.
- Taking part is completely voluntary and will not affect your standard NHS care rights.
Who may be eligible?
This trial is open to adults aged 18 and over who have recently been diagnosed with multiple myeloma and have finished an autologous stem cell transplant as part of their initial treatment.
To be suitable, sensitive lab tests must show that a tiny number of myeloma cells are still present in your bone marrow (MRD-positive). Participants also need to be in generally good health and have recovered well from their transplant so they can safely receive further treatment.
You may not be eligible if your cancer has already grown or returned, if tests show no remaining cancer cells, or if you have certain other serious medical conditions, such as severe heart or kidney problems.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have newly diagnosed multiple myeloma.
- I have recently completed a stem cell transplant using my own cells.
- My recent tests show small traces of myeloma cells remaining (MRD-positive).
- I am generally well enough to attend regular hospital appointments.
What does participation involve?
If you take part, you will be placed by chance (randomised) into one of two treatment groups. One group receives the new combination of teclistamab and talquetamab, given as injections under the skin. The other group receives standard treatment with daratumumab injections and lenalidomide capsules taken by mouth.
You will need to visit the hospital regularly for your treatments, safety check-ups, and routine blood tests. At set times, you will have bone marrow tests to check if any myeloma cells remain. You will also be asked to fill in simple questionnaires about your symptoms and daily wellbeing. The active treatment usually lasts for up to one to two years, followed by regular long-term check-ups to monitor your health.
Potential risks and benefits
Locations (1)
- —UnverifiedPoland
Common questions
What does being 'MRD-positive' mean?
It means that although your treatment worked very well, specialised tests can still find tiny, microscopic traces of myeloma cells in your bone marrow.
Can I choose which treatment group I join?
No. A computer assigns you to a group by chance. This process is called randomisation and ensures the comparison between treatments is fair.
Will taking part cost me anything?
No. Trial medicines and extra tests are provided free of charge, and many studies offer help with travel costs to and from hospital visits.
What happens if I decide to stop the trial?
You can leave the study at any time. Your medical team will discuss standard treatment options with you, and your ongoing care will not be affected.
How are the medicines given?
Teclistamab, talquetamab, and daratumumab are given as injections under the skin, while lenalidomide is taken as capsules by mouth at home.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.